Format

Send to

Choose Destination
J Immunotoxicol. 2017 Dec;14(1):31-38. doi: 10.1080/1547691X.2016.1254305.

Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response.

Author information

1
a Drug Safety Research and Development, Pfizer Inc. , Groton , CT , USA.
2
b Drug Safety Research and Development, Pfizer Inc. , La Jolla , CA , USA.
3
c National Institute of Diabetes and Digestive and Kidney Diseases, NIH , Bethesda , MD , USA.
4
d Department of Internal Medicine , University of North Carolina , Chapel Hill , NC , USA.
5
e Department of Internal Medicine , University of Michigan , Ann Arbor , MI , USA.
6
f Department of Internal Medicine , IUPUI , Indianapolis , IN , USA.
7
g Department of Internal Medicine , Wake Forest University School of Medicine , Winston-Salem , NC , USA.

Abstract

Drug-induced liver injury (DILI) is a growing problem. Diagnostic methods to differentiate DILI caused by an adaptive immune response from liver injury of other causes or to identify the responsible drug in patients receiving multiple drugs, herbals and/or dietary supplements (polypharmacy) have not yet been established. The lymphocyte transformation test (LTT) has been proposed as a diagnostic method to determine if a subject with an apparent hypersensitivity reaction has become sensitized to a specific drug. In this test, peripheral blood mononuclear cells (PBMC) collected from a subject are incubated with drug(s) suspected of causing the reaction. Cell proliferation, measured by the incorporation of [3H]-thymidine into new DNA, is considered evidence of a drug-specific immune response. The objectives of the current studies were to: (1) develop and optimize a modified version of the LTT (mLTT) and (2) investigate the feasibility of using the mLTT for diagnosing DILI associated with an adaptive immune response and identifying the responsible drug. PBMC collected from donors with a history of drug hypersensitivity reactions to specific drugs (manifested as skin rash) were used as positive controls for assay optimization. Following optimization, samples collected from 24 subjects enrolled in the U.S. Drug-Induced Liver Injury Network (DILIN) were tested in the mLTT. Using cytokine and granzyme B production as the primary endpoints to demonstrate lymphocyte sensitization to a specific drug, most samples from the DILIN subjects failed to respond. However, robust positive mLTT responses were observed for two of four samples from three DILIN subjects with hepatitis due to isoniazid (INH). We conclude that the mLTT, as performed here on frozen and thawed PBMC, is not a reliable test for diagnosing DILI caused by all drugs, but that it may be useful for confirming the role of the adaptive immune response in DILI ascribed to INH.

KEYWORDS:

Allergic reactions; drug-induced liver injury; drugs; hepatitis; immuno-allergic; lymphocyte transformation test; lymphocytes

PMID:
28121193
PMCID:
PMC5505862
DOI:
10.1080/1547691X.2016.1254305
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center